Physician profile
Nischal Raya
NPI 1326429747
$37,921.18
in general payments reported to CMS, 2019-2025
28 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2021: $184 · 2022: $1,440 · 2023: $971 · 2024: $21K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $32K · Food and Beverage: $3,998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $32,072.21 |
| Food and Beverage | $3,998.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $33,959.21 | 2022-2025 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $1,098.33 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $775.63 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $378.57 | 2022-2025 | Dupixent |
| Genzyme Corporation | $308.30 | 2019-2025 | |
| Amgen INC. | $236.93 | 2022-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.14 | 2021-2025 | Ofev, Jascayd |
| Grifols USA, LLC | $149.56 | 2021-2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $145.17 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $97.58 | 2021-2025 | Cuvitru, Glassia |
| Mallinckrodt Hospital Products INC. | $82.02 | 2022-2024 | Acthar |
| Merck Sharp & Dohme LLC | $72.77 | 2022-2024 | Zerbaxa, Recarbrio, Dificid |
| Pulmonx Corporation | $62.82 | 2022-2023 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Mylan Specialty L.P. | $43.05 | 2022-2024 | Yupelri |
| Ethicon INC. | $38.91 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $38.85 | 2022-2023 | Smartvest |
| Jazz Pharmaceuticals INC. | $37.90 | 2021-2022 | |
| Melinta Therapeutics, LLC | $28.30 | 2023 | Rezzayo, Vabomere |
| Tactile Systems Technology INC | $24.42 | 2022 | |
| United Therapeutics Corporation | $22.00 | 2025 | Tyvaso |
| Insmed, INC. | $17.93 | 2024 | Arikayce |
| Viatris Specialty LLC | $17.79 | 2025 | Yupelri |
| Alexion Pharmaceuticals, INC. | $17.72 | 2022 | |
| Fisher & Paykel Healthcare INC | $17.49 | 2025 | Fisher & Paykel Healthcare |
| Baxter Healthcare | $17.43 | 2022 | |
| Ani Pharmaceuticals, INC. | $16.60 | 2024 | Purified Cortrophin Gel |
| Inogen, INC. | $15.97 | 2025 | |
| Paratek Pharmaceuticals, INC. | $15.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nischal Raya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.